Get the Stockscreener App
3.04
1.33%
0.04
Pre-market:
3.01
-0.03
-0.99%
Editas Medicine Inc stock is traded at $3.04, with a volume of 1.26M.
It is up +1.33% in the last 24 hours and up +13.86% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
See More
Previous Close:
$3.00
Open:
$3.02
24h Volume:
1.26M
Relative Volume:
0.78
Market Cap:
$297.63M
Revenue:
$40.52M
Net Income/Loss:
$-160.06M
P/E Ratio:
-1.6141
EPS:
-1.8834
Net Cash Flow:
$-165.85M
1W Performance:
-0.65%
1M Performance:
+13.86%
6M Performance:
+9.35%
1Y Performance:
+97.40%
1-Day Range:
$2.92
$3.16
1-Week Range:
$2.77
$3.16
52-Week Range:
$1.29
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.04 | 297.63M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Chardan Capital Boosts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat
Editas Medicine (NASDAQ: EDIT) cuts Q1 2026 loss as spending falls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results - MarketBeat
Editas Medicine Releases Q1 2026 Financial Results - AlphaStreet
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Editas Medicine (Nasdaq: EDIT) trims Q1 2026 net loss to $25M - Stock Titan
Editas: Q1 Earnings Snapshot - Barchart.com
Editas targets human testing this year for a one-shot cholesterol gene edit - Stock Titan
Editas Medicine Announces First Quarter 2026 Results and Business Updates - Yahoo Finance
Editas Medicine (EDIT) to Release Quarterly Earnings on Monday - MarketBeat
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) Rating Increased to Hold at Wall Street Zen - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving AverageHere's Why - MarketBeat
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDITAS Medicine (NASDAQ: EDIT) advances EDIT-401; IND target mid-2026 - Stock Titan
Editas Medicine (NASDAQ: EDIT) details 2026 virtual meeting, pay vote and in vivo strategy - Stock Titan
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Editas Medicine to present preclinical data on EDIT-401 therapy By Investing.com - Investing.com India
Editas Medicine to present preclinical data on EDIT-401 therapy - Investing.com UK
Upcoming Editas Medicine presentations focus on gene editing research advances - Traders Union
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - ChartMill
Attachment - GlobeNewswire
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow | Editas Medicine Inc - Stock Titan
Is Editas Medicine going to $0? - MSN
Editas Medicine : Corporate Effectiveness Report April 2026 (b08b29) - marketscreener.com
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Editas (EDIT) up 3.8% since last earnings report: Can it continue? - MSN
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell - MarketBeat
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026 - Minichart
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com India
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com - Investing.com South Africa
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young - Stock Titan
Growth Value: How correlated is Editas Medicine Inc to the S P500Sell Signal & Safe Capital Investment Plans - baoquankhu1.vn
Can Editas Medicine (EDIT) Stock Beat the Market | Price at $2.73, Up 2.25%Institutional Grade Picks - Cổng thông tin điện tử tỉnh Lào Cai
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Eastern Progress
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):